Literature DB >> 26770526

Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.

Lin Zhu1, Jing Zhang2, Hongtao Song2, Qinghua Wang3, Jianming Tan3, Weizhen Wu3, Meiqin Lin2.   

Abstract

The aim of this study was to establish clinical and genetic factors-based individual administration model of tacrolimus for Chinese Han patients after renal transplantation (RT). The genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 in 216 RT patients were detected by PCR-RFLP, the genetic and clinical factors and blood concentration/dose × body weight (C/D) values of tacrolimus were performed the single factor correlation analysis, and established the dose prediction algorithm of tacrolimus by stepwise multiple regression analysis. CYP3A5*3, hematocrit and albumin were correlated with the C/D values of tacrolimus, the best regression model could explain 28.3% reason of individual dose differences of tacrolimus, among which CYP3A5*3 polymorphism could explain 23.5%. The genetic factors played an important role in the dose differences of tacrolimus, the patients should be checked CYP3A5*3 genotype before administration of tacrolimus to predict the tacrolimus doses, thus helping to improve the safety and effectiveness of tacrolimus application.

Entities:  

Keywords:  CYP3A4; CYP3A5; MDR1; Tacrolimus; genetic polymorphism; individualized medication; renal transplantation

Year:  2015        PMID: 26770526      PMCID: PMC4694426     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  21 in total

1.  Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

Authors:  Hiromi Fukushima-Uesaka; Yoshiro Saito; Hidemi Watanabe; Kisho Shiseki; Mayumi Saeki; Takahiro Nakamura; Kouichi Kurose; Kimie Sai; Kazuo Komamura; Kazuyuki Ueno; Shiro Kamakura; Masafumi Kitakaze; Sotaro Hanai; Toshiharu Nakajima; Kenji Matsumoto; Hirohisa Saito; Yu-ichi Goto; Hideo Kimura; Masaaki Katoh; Kenji Sugai; Narihiro Minami; Kuniaki Shirao; Tomohide Tamura; Noboru Yamamoto; Hironobu Minami; Atsushi Ohtsu; Teruhiko Yoshida; Nagahiro Saijo; Yutaka Kitamura; Naoyuki Kamatani; Shogo Ozawa; Jun-ichi Sawada
Journal:  Hum Mutat       Date:  2004-01       Impact factor: 4.878

Review 2.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 3.  An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.

Authors:  Satohiro Masuda; Ken-ichi Inui
Journal:  Pharmacol Ther       Date:  2006-06-08       Impact factor: 12.310

4.  Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.

Authors:  Pierre Wallemacq; Victor W Armstrong; Merce Brunet; Vincent Haufroid; David W Holt; Atholl Johnston; Dirk Kuypers; Yannick Le Meur; Pierre Marquet; Michael Oellerich; Eric Thervet; Burkhand Toenshoff; Nas Undre; Lutz T Weber; Ian S Westley; Michel Mourad
Journal:  Ther Drug Monit       Date:  2009-04       Impact factor: 3.681

5.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

6.  Optimization of initial tacrolimus dose using pharmacogenetic testing.

Authors:  E Thervet; M A Loriot; S Barbier; M Buchler; M Ficheux; G Choukroun; O Toupance; G Touchard; C Alberti; P Le Pogamp; B Moulin; Y Le Meur; A E Heng; J F Subra; P Beaune; C Legendre
Journal:  Clin Pharmacol Ther       Date:  2010-04-14       Impact factor: 6.875

7.  Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.

Authors:  X-J Shi; F Geng; Z Jiao; X-Y Cui; X-Y Qiu; M-K Zhong
Journal:  J Clin Pharm Ther       Date:  2010-10-05       Impact factor: 2.512

8.  Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Authors:  Norihiko Tsuchiya; Shigeru Satoh; Hitoshi Tada; Zhenhua Li; Chikara Ohyama; Kazunari Sato; Toshio Suzuki; Tomonori Habuchi; Tetsuro Kato
Journal:  Transplantation       Date:  2004-10-27       Impact factor: 4.939

9.  Human P-glycoprotein transports cyclosporin A and FK506.

Authors:  T Saeki; K Ueda; Y Tanigawara; R Hori; T Komano
Journal:  J Biol Chem       Date:  1993-03-25       Impact factor: 5.157

Review 10.  Genetic variability in CYP3A5 and its possible consequences.

Authors:  Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

View more
  1 in total

1.  CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients.

Authors:  Yilei Yang; Xin Huang; Yinping Shi; Rui Yang; Haiyan Shi; Xinmei Yang; Guoxiang Hao; Yi Zheng; Jianning Wang; Lequn Su; Yan Li; Wei Zhao
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.